Sector News

Siegfried buys 95% stake in biotechnology firm DiNAMIQS

May 6, 2023
Life sciences

Switzerland-based Siegfried has purchased a 95% stake in DiNAMIQS, a biotechnology firm that focuses on the development and production of viral vectors for cell and gene therapies.

Siegfried will leverage DiNAMIQS’ capabilities to commercial scale by constructing a facility that complies with good manufacturing practice standards.

The facility will be situated with DiNAMIQS’ existing operations at Bio-Technopark in Zurich-Schlieren, Switzerland, and is anticipated to become operational in 2025.

DiNAMIQS’ parent company, DiNAQOR, will own the remaining 5% stake in the firm.

The deal includes an option for Siegfried to purchase this remaining 5% five years after the acquisition.

The move represents Siegfried’s strategy to expand its presence in biologics, and provides important growth opportunities in the mid to long term.

DiNAMIQS will initially continue to run under its own name and as a mostly independent venture within Siegfried.

DiNAMIQS and its clients will take advantage of the integration of its drug substances production activities into Siegfried’s capabilities, as well as the capacities for the aseptic filling and completion of complex biological entities at its facilities in Hameln, Germany, and Irvine in the US.

Siegfried CEO Dr Wolfgang Wienand stated: “With this acquisition, we are entering the rapidly growing space of cell and gene therapies where viral vector-based technologies support the majority of clinical candidates in a rich development pipeline.

“In our view, this approach of an initial small-scale acquisition of a highly capable technology platform followed by flexible bolt-on investments into capabilities and capacities in line with actual market needs, provides significant value upside at reasonable entry costs.

“This is perfectly in line with our EVOLVE strategy and our track record of disciplined execution of value-adding mergers and acquisitions – and a further step towards our vision of creating a leading contract development and managing organisation in our space.”

Source: pharmaceutical-technology.com

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach